Children will no longer be prescribed puberty blockers, NHS says

By Staff

Children will no longer be prescribed puberty blockers at gender identity clinics, NHS England has confirmed. The Government said it welcomed the “landmark decision”, adding it would help ensure care is based on evidence and is in the “best interests of the child”.

Puberty blockers, which pause the physical changes of puberty such as breast development or facial hair, will now only be available to children as part of clinical research trials. It follows a public consultation on the issue and an interim policy, and comes after NHS England commissioned an independent review in 2020 of gender identity services for children under 18.

That review, led by Dr Hilary Cass, followed a sharp rise in referrals to the Gender Identity Development Service (Gids) run by the Tavistock and Portman NHS Foundation Trust, which is closing at the end of March. In 2021/22, there were over 5,000 referrals to Gids, compared to just under 250 a decade earlier.

READ MORE: Majority of LGBT+ people face abuse on London transport as bystanders ‘do nothing to help’

The clinic has come under repeated scrutiny. In February 2022, Dr Cass published an interim report saying there was a need to move away from one unit and recommended the creation of regional services to better support youngsters.

She also pointed to a lack of long-term evidence and data collection on what happens to children and young people who are prescribed medication.

She added that Gids had not collected routine and consistent data “which means it is not possible to accurately track the outcomes and pathways that children and young people take through the service.”

Following the Tavistock’s closure, two new NHS services will now open in early April, situated in London’s Great Ormond Street Hospital and Alder Hey Children’s Hospital in Liverpool.

The NHS has said children attending these clinics will be supported by clinical experts in neurodiversity, paediatrics and mental health, “resulting in a holistic approach to care”.

Health minister, Maria Caulfield, said: “We have always been clear that children’s safety and wellbeing is paramount, so we welcome this landmark decision by the NHS.”

“Ending the routine prescription of puberty blockers will help ensure that care is based on evidence, expert clinical opinion and is in the best interests of the child.”

No adverts or pop-ups! Just our brilliant MyLondon stories, breaking news and features presented in the best way possible.

Get your free one-month trial by visiting the ‘Premium’ tab on the MyLondon app now (auto renews annually at £19.99).

If you haven’t got the app already, get started by downloading it here on iPhone or here on Android. If you already have the app but can’t see the ‘Premium’ section, you’ll need to check for the latest update. More info here.

The consultation on the future of services received more than 4,000 responses, including around a quarter from members of the public, 22% from patients, 21% from parents, 10% from trans adults and 5% from clinicians.

John Stewart, national director of specialised commissioning at NHS England, told the PA news agency: “Given that the debate is often very polarised, so too were the responses to the consultation.”

“Many people said the policy didn’t go far enough in terms of still allowing potential access (to puberty blockers) through research, and others saying clearly they disagreed fundamentally and that these should be routinely available to everyone who believes they need it.”

Regarding the new clinics, he said: “This is just the first step in building a regional model, where our aim is to establish between seven and eight specialist centres including the north and the south hubs over the next year to two years.”

Around 250 patients are expected to be transferred to the new clinics from Gids when they open.

Some 5,000 more children and young people are currently on the waiting list for referral into the new clinics.

Mr Stewart said: “Our two new providers on their own are not going to be able to make a significant dent immediately in that waiting list, but what they are doing is helping us establish a new and fundamentally different service model, in line with advice from the Cass review.”

He said other regional centres could hopefully be commissioned quickly “and once we get to that point we should begin to see significant movement in that waiting list and numbers falling.”

“The speed and pace at which the clinics will be able to see new patients off the waiting list is in large part going to be dependent on how successful their ongoing recruitment into the service is, and that is not straightforward.”

Fewer than 100 young people are currently on puberty blockers.

They will be able to continue their treatment and are being seen by specialist endocrine services at Leeds and University College London Hospital.

It is understood NHS England hopes to have a study into the use of puberty blockers in place by December 2024, with eligibility criteria yet to be decided.

A Stonewall spokesperson said: “All trans young people deserve access to high quality, timely healthcare. For some, an important part of this care comes in the form of puberty blockers, a reversible treatment that delays the onset of puberty, prescribed by expert endocrinologists, giving the young person extra time to evaluate their next steps.

We are concerned that NHS England will be putting new prescriptions on hold until a research protocol is up and running at the end of 2024. This change will not affect young people who have already been prescribed puberty blockers. The group who it will affect are young people who are currently in the system, but who haven’t been referred to the endocrine pathway.”

? Sign up to our daily newsletters for all the latest and greatest from across London here.

Share This Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *